Preferred Label : canakinumab;

MeSH note : a human anti-interleukin-1beta monoclonal antibody for treatment of cryopyrin-associated periodic syndrome;

CISMeF synonym : immunoglobulin G1, anti-(human interleukin 1beta) (human clone ACZ885 heavy chain V region);

MeSH hyponym : ACZ885;

Is substance : O;

UNII : 37CQ2C7X93;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3518649/fr/ilaris-canakinumab-crise-d-arthrite-goutteuse
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
Acute gout (disorder)
canakinumab
injections, subcutaneous
evaluation of the transparency committee
canakinumab
arthritis, gouty

---
https://www.has-sante.fr/jcms/p_3539069/fr/ilaris-canakinumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
canakinumab
injections, subcutaneous
chronic disease
biological therapy

---
http://www.lecrat.eu/?s=Canakinumab+-+Grossesse+et+allaitement
2023
false
false
false
France
French
drug information
pregnancy
breast feeding
canakinumab

---
https://www.has-sante.fr/jcms/p_3222371/fr/ilaris-maladie-de-still
2020
false
false
false
France
insurance, health, reimbursement
treatment outcome
canakinumab
Interleukin-1beta
injections, subcutaneous
Still's disease, Adult-Onset
guidelines for drug use
adult
evaluation of the transparency committee
canakinumab
antibodies, monoclonal

---
https://www.has-sante.fr/portail/jcms/c_2969189/fr/ilaris
2019
false
false
false
France
Still's disease, Adult-Onset
canakinumab
canakinumab
injections, subcutaneous
evaluation of the transparency committee
antibodies, monoclonal

---
https://pharmactuel.com/index.php/pharmactuel/article/view/1237
2019
false
false
false
false
France
canakinumab
injections, subcutaneous
myocardial infarction
treatment outcome
C-reactive protein
anti-inflammatory agents
anti-inflammatory agents
cardiovascular diseases
stroke
atherosclerosis
critical appraisal or critical reading
myocardial infarction
canakinumab
antibodies, monoclonal
antibodies, monoclonal

---
https://www.has-sante.fr/jcms/c_2806295/fr/ilaris-canakinumab-inhibiteur-de-l-interleukine-1
2018
false
true
false
France
guidelines for drug use
adult
adolescent
child
insurance, health, reimbursement
treatment outcome
periodic fever, familial, autosomal dominant
hyperimmunoglobulinemia D
familial mediterranean fever
injections, subcutaneous
canakinumab
evaluation of the transparency committee
interleukin inhibitors
Interleukin-1beta
canakinumab
mevalonate kinase deficiency
antibodies, monoclonal
fever
hereditary autoinflammatory diseases

---
https://www.has-sante.fr/portail/jcms/c_2806295/fr/ilaris-canakinumab-inhibiteur-de-l-interleukine-1
2017
false
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
canakinumab
canakinumab
canakinumab
injections, subcutaneous
guidelines for drug use
familial mediterranean fever
periodic fever, familial, autosomal dominant
mevalonate kinase deficiency
antibodies, monoclonal
antibodies, monoclonal
fever
hereditary autoinflammatory diseases

---
http://www.has-sante.fr/portail/jcms/c_2040093/fr/ilaris
2015
true
France
French
English
arthritis, juvenile
rheumatoid arthritis, systemic juvenile
arthritis, gouty
canakinumab
antibodies, monoclonal
injections, subcutaneous
canakinumab
cryopyrin-associated periodic syndromes
insurance, health, reimbursement
adult
adolescent
child
aged
treatment outcome
evaluation of the transparency committee

---
http://www.has-sante.fr/portail/jcms/c_1743367/fr/ilaris-canakinumab-inhibiteur-de-linterleukine-1
2014
false
France
French
canakinumab
canakinumab
canakinumab
Interleukin-1beta
injections, subcutaneous
treatment outcome
insurance, health, reimbursement
continuity of patient care
drug monitoring
guidelines for drug use
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal
adult
arthritis, gouty
corticosteroid therapy

---
http://www.has-sante.fr/portail/jcms/c_1735624/fr/ilaris-canakinumab-inhibiteur-de-linterleukine-1
http://www.has-sante.fr/portail/jcms/c_1735624/fr/ilaris
2014
false
France
French
canakinumab
canakinumab
canakinumab
Interleukin-1beta
injections, subcutaneous
child, preschool
treatment outcome
insurance, health, reimbursement
risk management
continuity of patient care
drug monitoring
guidelines for drug use
evaluation of the transparency committee
antibodies, monoclonal
antibodies, monoclonal
arthritis, juvenile
rheumatoid arthritis, systemic juvenile
corticosteroid therapy

---
http://www.has-sante.fr/portail/jcms/c_1743367/fr/ilaris
2014
false
false
false
France
French
evaluation of the transparency committee
canakinumab
injections, subcutaneous
canakinumab
arthritis, gouty
insurance, health, reimbursement
treatment outcome
Gout attack
canakinumab
continuity of patient care
clinical trials, phase iii as topic
guidelines for drug use
Interleukin-1beta
corticosteroid therapy
antibodies, monoclonal
antibodies, monoclonal

---
http://www.has-sante.fr/portail/jcms/c_1725323/fr/ilaris
2014
France
French
canakinumab
canakinumab
canakinumab
cryopyrin-associated periodic syndromes
Interleukin-1beta
injections, subcutaneous
child, preschool
treatment outcome
insurance, health, reimbursement
risk management
continuity of patient care
drug monitoring
guidelines for drug use
evaluation of the transparency committee
rare diseases
familial cold autoinflammatory syndrome
Muckle-Wells syndrome
chronic infantile neurological, cutaneous, and articular syndrome
antibodies, monoclonal
antibodies, monoclonal

---
http://www.cri-net.com/fiches-pratiques-et-recommandations/prise-en-charge-pratique-des-patients-sous-anti-il1
2013
false
true
false
France
French
interleukin 1 receptor antagonist protein
interleukin 1 receptor antagonist protein
patient care management
continuity of patient care
guidelines for drug use
practice guideline
patients guideline
consensus
adolescent
child
adult
arthritis, rheumatoid
anakinra
anakinra
canakinumab
canakinumab
anakinra
canakinumab
Interleukin-1beta
cryopyrin-associated periodic syndromes
Juvenile-Onset still disease
Still's disease, Adult-Onset
rheumatoid arthritis, systemic juvenile
Idiopathic recurrent pericarditis
pericarditis
Castleman Disease
schnitzler syndrome
familial mediterranean fever
Erdheim-Chester disease
rare diseases
mevalonate kinase deficiency
periodic fever, familial, autosomal dominant
rilonacept
rilonacept
rilonacept
injections, subcutaneous
arthritis, juvenile
antibodies, monoclonal
antibodies, monoclonal
fever
hereditary autoinflammatory diseases
recombinant fusion proteins
recombinant fusion proteins

---
http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=61415541
2013
summary of product characteristics
powders
injections
canakinumab

---
http://www.meddispar.fr/Medicaments/ILARIS-150-B-1/(type)/letter/(value)/I/(cip)/3400921787597
2013
false
false
France
French
canakinumab
drug prescriptions
legislation, drug
continuity of patient care
drug monitoring
canakinumab
cryopyrin-associated periodic syndromes
drug information
antibodies, monoclonal

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=66684652
2012
France
summary of product characteristics
package leaflet
powders
canakinumab
injections

---
http://www.meddispar.fr/Medicaments/ILARIS-150-B-1/(type)/letter/(value)/I/(cip)/3400939745763
2011
France
French
antibodies, monoclonal
canakinumab
injections, subcutaneous
drug prescriptions
legislation, drug
canakinumab
drug information

---
https://www.ema.europa.eu/medicines/human/EPAR/Ilaris
2011
United Kingdom
English
French
syndication feed
canakinumab
antibodies, monoclonal
canakinumab
antibodies, monoclonal
orphan drug production
Interleukin-1beta
drug approval
drug labeling
treatment outcome
adult
child
adolescent
cryopyrin-associated periodic syndromes
injections, subcutaneous
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
drug compounding
canakinumab
drug evaluation
summary of product characteristics
package leaflet
arthritis, juvenile
arthritis, gouty
Systemic-onset juvenile idiopathic arthritis

---
http://www.has-sante.fr/portail/jcms/c_928146/ilaris
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-03/ilaris_-_ct-7256.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-02/ilaris_ct_7256.pdf
2010
France
French
English
canakinumab
antibodies, monoclonal
injections, subcutaneous
canakinumab
orphan drug production
cryopyrin-associated periodic syndromes
insurance, health, reimbursement
adult
adolescent
child
aged
treatment outcome
canakinumab
antibodies, monoclonal
antibodies, monoclonal
evaluation of the transparency committee

---
Nous contacter.
02/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.